Flunisolide aerosol in treatment of steroid-dependent asthma in children.
The efficacy of flunisolide aerosol in permitting the reduction of oral steroid dosage without deterioration of asthma was studied in 34 children requiring at least 10 mg prednisone g.o.d. This was a double-blind, placebo-controlled, parallel study lasting 14 weeks. Progress was evaluated daily by symptom scores, bronchodilator use and Wright Peak Flow measurement and every two weeks by spirometry and physical examination. Adrenal function and throat culture for Candida were evaluated before and after the study period. Similar reduction in mean prednisone dosage was achieved in flunisolide and placebo patients. However, flunisolide patients improved and placebo patients deteriorated clinically. These changes were gradual and frequently not detected at bi-weekly evaluation. No patient developed thrush, adrenal suppression or other adverse reaction. Flunisolide aerosol was shown to be safe, acceptable and effective in permitting reduction of oral steroid dosage without increase in symptoms.
D000293:Adolescent; D000336:Aerosols; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D010919:Placebos; D011241:Prednisone / Q000627:therapeutic use
D000336:Aerosols; D010919:Placebos; D005446:Fluocinolone Acetonide; C007734:flunisolide; D011241:Prednisone